These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 17697139)
1. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. Fontana P; Hulot JS; De Moerloose P; Gaussem P J Thromb Haemost; 2007 Oct; 5(10):2153-5. PubMed ID: 17697139 [No Abstract] [Full Text] [Related]
2. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Hulot JS; Bura A; Villard E; Azizi M; Remones V; Goyenvalle C; Aiach M; Lechat P; Gaussem P Blood; 2006 Oct; 108(7):2244-7. PubMed ID: 16772608 [TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210 [TBL] [Abstract][Full Text] [Related]
4. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275 [TBL] [Abstract][Full Text] [Related]
5. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986 [TBL] [Abstract][Full Text] [Related]
6. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435 [TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659 [TBL] [Abstract][Full Text] [Related]
8. CYP2C19 genotype and outcomes of clopidogrel treatment. Siasos G; Tousoulis D; Stefanadis C N Engl J Med; 2011 Feb; 364(5):481-2. PubMed ID: 21288101 [No Abstract] [Full Text] [Related]
9. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. Umemura K; Furuta T; Kondo K J Thromb Haemost; 2008 Aug; 6(8):1439-41. PubMed ID: 18532997 [No Abstract] [Full Text] [Related]
10. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms. Chen BL; Zhang W; Li Q; Li YL; He YJ; Fan L; Wang LS; Liu ZQ; Zhou HH Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):904-8. PubMed ID: 18346178 [TBL] [Abstract][Full Text] [Related]
12. Clopidogrel, genetics, and drug responsiveness. Freedman JE; Hylek EM N Engl J Med; 2009 Jan; 360(4):411-3. PubMed ID: 19164193 [No Abstract] [Full Text] [Related]
13. Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms. Perry E Am J Health Syst Pharm; 2011 Mar; 68(6):529-32. PubMed ID: 21378302 [No Abstract] [Full Text] [Related]
14. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Jinnai T; Horiuchi H; Makiyama T; Tazaki J; Tada T; Akao M; Ono K; Hoshino K; Naruse Y; Takahashi K; Watanabe H; Kita T; Kimura T Circ J; 2009 Aug; 73(8):1498-503. PubMed ID: 19531897 [TBL] [Abstract][Full Text] [Related]
15. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091 [TBL] [Abstract][Full Text] [Related]
16. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Gong IY; Crown N; Suen CM; Schwarz UI; Dresser GK; Knauer MJ; Sugiyama D; DeGorter MK; Woolsey S; Tirona RG; Kim RB Eur Heart J; 2012 Nov; 33(22):2856-2464a. PubMed ID: 22374717 [TBL] [Abstract][Full Text] [Related]
17. CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention. Mejin M; Tiong WN; Lai LY; Tiong LL; Bujang AM; Hwang SS; Ong TK; Fong AY Int J Clin Pharm; 2013 Aug; 35(4):621-8. PubMed ID: 23661171 [TBL] [Abstract][Full Text] [Related]
18. The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature. Fefer P; Matetzky S Thromb Haemost; 2011 Aug; 106(2):203-10. PubMed ID: 21792462 [TBL] [Abstract][Full Text] [Related]
19. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858 [TBL] [Abstract][Full Text] [Related]
20. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. Holmes MV; Perel P; Shah T; Hingorani AD; Casas JP JAMA; 2011 Dec; 306(24):2704-14. PubMed ID: 22203539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]